GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies

The power of genome-wide SNP association studies is limited, among others, by the large number of false positive test results. To provide a remedy, we combined SNP association analysis with the pathway-driven gene set enrichment analysis (GSEA), recently developed to facilitate handling of genome-wide gene expression data. The resulting GSEA-SNP method rests on the assumption that SNPs underlying a disease phenotype are enriched in genes constituting a signaling pathway or those with a common regulation. Besides improving power for association mapping, GSEA-SNP may facilitate the identification of disease-associated SNPs and pathways, as well as the understanding of the underlying biological mechanisms. GSEA-SNP may also help to identify markers with weak effects, undetectable in association studies without pathway consideration. The program is freely available and can be downloaded from our website.

[1]  M. Orešič,et al.  Pathways to the analysis of microarray data. , 2005, Trends in biotechnology.

[2]  T. Force,et al.  p38 mitogen-activated protein kinase: a future target for heart failure therapy? , 2006, Journal of the American College of Cardiology.

[3]  D. Clayton,et al.  Genome-wide association studies: theoretical and practical concerns , 2005, Nature Reviews Genetics.

[4]  Kai Wang,et al.  Pathway-based approaches for analysis of genomewide association studies. , 2007, American journal of human genetics.

[5]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R Aikawa,et al.  MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. , 1999, Circulation.

[7]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[8]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[9]  Ye Xiong,et al.  Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. , 2006, Free radical biology & medicine.

[10]  Leszek Wojnowski,et al.  Dystrophin‐deficiency increases the susceptibility to doxorubicin‐induced cardiotoxicity , 2007, European journal of heart failure.

[11]  Joy Joseph,et al.  Doxorubicin-induced apoptosis: Implications in cardiotoxicity , 2002, Molecular and Cellular Biochemistry.

[12]  Joseph L. Gastwirth,et al.  Trend Tests for Case-Control Studies of Genetic Markers: Power, Sample Size and Robustness , 2002, Human Heredity.

[13]  Yongchao Ge Resampling-based Multiple Testing for Microarray Data Analysis , 2003 .

[14]  J. Klein,et al.  Suppression by Metallothionein of Doxorubicin-induced Cardiomyocyte Apoptosis through Inhibition of p38 Mitogen-activated Protein Kinases* , 2000, The Journal of Biological Chemistry.

[15]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[16]  A Bast,et al.  The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro , 2003, British Journal of Cancer.